Skip to main content
Log in

No role for the CYP3A5*3 polymorphism in intestinal and hepatic metabolism of midazolam

  • Letter to the Editors
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kharasch ED, Walker A, Isoherranen N, Hoffer C, Sheffels P, Thummel K et al (2007) Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. Clin Pharmacol Ther 82:410–426

    Article  PubMed  CAS  Google Scholar 

  2. Kasel D, Harlfinger S, Kinzig-Schippers M, Sörgel F, Gebhardt W, Fuhr U (2002) Determination of midazolam in human plasma using LC-MS/MS devices from two different manufacturers. Eur J Clin Pharmacol 58:87

    Google Scholar 

  3. Tomalik-Scharte D, Jetter A, Kinzig-Schippers M, Skott A, Sörgel F, Klaassen T et al (2005) Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers. Drug Metab Dispos 33:1859–1866

    PubMed  CAS  Google Scholar 

Download references

 

Conflict of interest statement

The authors declare no conflict of interest

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to D. Tomalik-Scharte.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tomalik-Scharte, D., Doroshyenko, O., Kirchheiner, J. et al. No role for the CYP3A5*3 polymorphism in intestinal and hepatic metabolism of midazolam. Eur J Clin Pharmacol 64, 1033–1035 (2008). https://doi.org/10.1007/s00228-008-0503-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-008-0503-9

Keywords

Navigation